Avantor (AVTR) just delivered a clear profitability reset. Fresh third quarter numbers show sales of US$1,698.3 million and net income of US$203.4 million, compared with a net loss in the prior year period.
Avantor's latest earnings reset has arrived after a strong run in the share price. A 90 day share price return of 13.83% and a year to date share price gain of 34.99% hint at building momentum, despite a weaker 3 year total shareholder return of 16.65% and a 5 year total shareholder return decline of 59.32%.
Scan other life sciences suppliers that show similar earnings momentum to Avantor using the hand-picked 19 high quality undiscovered gems, which match strong fundamentals with under-the-radar share price profiles.
After a sharp rebound in Avantor's earnings and a strong year to date share price gain, the real choice now is simple: pay up for the reset today or wait for a cheaper entry and risk missing it.
Avantor's most followed narrative pegs fair value at $17.35 per share, versus a last close of $15.47. This frames the recent profitability reset as only part of a longer turnaround story that investors are weighing against execution risk.
Enterprise-wide Revival actions, including the new two segment model, leadership refresh and kaizen driven manufacturing work, are intended to reshape Avantor’s commercial approach and cost base. These efforts could support steadier organic revenue and earnings progression as the program matures.
See why 10 investors see Avantor as 11% undervalued.
Result: Fair Value of $17.35 (UNDERVALUED)
Still, the bullish Avantor story can break if competitive pressure in lab distribution persists or if weak funding in biotech and academia continues to keep organic growth under strain.
Find out about the key risks to this Avantor narrative.
Mixed on Avantor so far or firmly in one camp already? Act while the reset story is fresh and weigh both the upside and the red flags through 3 key rewards and 1 important warning sign.
If Avantor's reset has your attention, do not stop here. Broaden your watchlist, pressure test your convictions, and give yourself more ways to put capital to work.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com